Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Wild Ride Along The Total Product Life Cycle For Dan Schultz

This article was originally published in The Gray Sheet

Executive Summary

It might be said that the tenure of Dan Schultz as CDRH director was a roller coaster ride around the total product life cycle
Advertisement

Related Content

Schultz Exits: Pressures From Inside And Out Catch Up With CDRH Director
Schultz Exits: Pressures From Inside And Out Catch Up With CDRH Director
Misperceptions And Missteps: Schultz Speaks Out On CDRH Struggles
Device Center Discord: 510(k) Review Process Is Flash Point At CDRH
FDA Device Chief Issues Caution On 510(k)s: Data Requests Could Get Steeper
Congress Approves FDA Reform/User Fee Bill In The Nick Of Time
CDRH Unveils Postmarket Safety “Action Items”
Postmarket Takes Spotlight: Guidant Recalls Reshuffle FDA And Device Industry Objectives For 2006
Postmarket Takes Spotlight: Guidant Recalls Reshuffle FDA And Device Industry Objectives For 2006

Topics

Advertisement
UsernamePublicRestriction

Register

MT027778

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel